Sign in Subscribe
Trademarks

Cantex Pharmaceuticals Trademark Application for "CANTEX" Finalized

Strategic Insights

— 1 min read

Cantex Pharmaceuticals, Inc., a prominent biopharmaceutical company, has successfully submitted a trademark application for "CANTEX" to the United States Patent and Trademark Office (USPTO). The application, processed by Clark+Elbing LLP, was made available to the public on October 18, 2025. The application focuses on pharmaceutical products, including Receptor for Advanced Glycation End products (RAGE) inhibitors, which target various serious illnesses such as cancer, infectious diseases, and autoimmune diseases.

Key Takeaways:

  • The trademark application, submitted by Cantex Pharmaceuticals, Inc., is for the name "CANTEX" under international trademark goods and services class codes 005, 044, and 045.
  • The application covers a wide range of pharmaceutical products, including Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses.
  • The products also include pharmaceutical preparations for the treatment and prevention of diseases and disorders in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases.
  • Licensing of pharmaceuticals and drug discovery technologies, as well as providing medical and scientific research information on diseases diagnosis and treatment, are also covered by the application.
  • The registrant information for this application is Michael J. Belliveau, Clark+Elbing LLP, located at One Financial Center, Suite 2110, Boston, MA 02111, United States.

Statistics:

  • The application serial number is 98043024.
  • The trademark application was made available to the public on October 18, 2025.
  • The application covers various classes of goods and services, including pharmaceuticals, licensing, and medical research information.
  • The company is focusing on Receptor for Advanced Glycation End products (RAGE) inhibitors, which fall under the broader category of cancer treatments.

Sources:

  • A News Reporter-Staff News Editor at Cancer Weekly
  • NewsRx journalists, Washington, D.C.
  • Clark+Elbing LLP, Boston, MA, United States
  • United States Patent and Trademark Office (USPTO)

Read more